Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centogene N.V. (NQ: CNTG )

0.3250 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3250
Bid (Size) 0.3500 (12)
Ask (Size) 0.3730 (1)
Prev. Close 0.3250
Today's Range 0.3250 - 0.3250
52wk Range 0.2511 - 1.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives Delisting Notice From Nasdaq
From Centogene NV
Via GlobeNewswire

Performance

YTD
-72.22%
-72.22%
1 Month
N/A
N/A
3 Month
+14.04%
+14.04%
6 Month
-27.78%
-27.78%
1 Year
-73.58%
-73.58%

More News

Read More
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
From Centogene NV
Via GlobeNewswire
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
From Centogene NV
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
From Centogene NV
Via GlobeNewswire
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
From Centogene NV
Via GlobeNewswire
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
From Centogene NV
Via GlobeNewswire
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
From Centogene NV
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CENTOGENE Receives Nasdaq Non-Compliance Notice
From Centogene NV
Via GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
From Centogene NV
Via GlobeNewswire
CENTOGENE Explores Strategic Alternatives
From Centogene NV
Via GlobeNewswire
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives French Research Tax Credit Accreditation
From Centogene NV
Via GlobeNewswire
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Preliminary Full Year 2023 Revenue
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Voting Results of Extraordinary General Meeting
From Centogene NV
Via GlobeNewswire
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
From Centogene NV
Via GlobeNewswire
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
From Centogene NV
Via GlobeNewswire
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
From Centogene NV
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.